Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation.

Sultan AS, Zimering Y, Petruzziello G, Alyea EP 3rd, Antin JH, Soiffer RJ, Ho VT, Sonis ST, Woo SB, Marty FM, Treister NS.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep;124(3):253-260. doi: 10.1016/j.oooo.2017.06.003. Epub 2017 Jun 16.

PMID:
28823316
2.

Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.

Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T.

Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.

3.

A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.

Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Kanamori H, Usuki K, Yamashita T, Watanabe M, Yakushiji K, Yano S, Nawa Y, Taguchi J, Takeuchi J, Tomiyama J, Nakamura Y, Miura I, Kanda Y, Takaue Y, Fukuda T.

Blood. 2011 Feb 17;117(7):2113-20. doi: 10.1182/blood-2010-05-285502. Epub 2010 Nov 24.

PMID:
21106987
4.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.

Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, Cabrera Marin JR, Espigado I, Solano C, Ferrà C, García-Noblejas A, Jimenez S, Sampol A, Yañez L, García-Gutiérrez V, Pascual MJ, Jurado M, Moraleda JM, Valcarcel D, Sanz MA, Carreras E, Duarte RF.

Biol Blood Marrow Transplant. 2016 Mar;22(3):584-8. doi: 10.1016/j.bbmt.2015.11.012. Epub 2015 Nov 26.

5.

Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.

Yamasaki S, Yoshimoto G, Ogawa R, Aoki K, Higuchi M, Harada N, Arima F, Kondo S, Matubara F, Takahashi T, Uike N, Miyamoto T, Okamura S, Akashi K; Fukuoka Blood and Marrow Transplantation Group.

Ann Hematol. 2015 Jul;94(7):1159-65. doi: 10.1007/s00277-015-2338-7. Epub 2015 Feb 24.

PMID:
25704584
6.

Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission.

Kurosawa S, Yamaguchi T, Uchida N, Miyawaki S, Usuki K, Watanabe M, Yamashita T, Kanamori H, Tomiyama J, Nawa Y, Yano S, Takeuchi J, Yakushiji K, Sano F, Uoshima N, Yano T, Nannya Y, Moriuchi Y, Miura I, Takaue Y, Fukuda T.

Biol Blood Marrow Transplant. 2011 Mar;17(3):401-11. doi: 10.1016/j.bbmt.2010.07.013. Epub 2010 Jul 25.

7.

Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML.

Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B, Burke M, Warlick E, Miller JS, Weisdorf D.

Bone Marrow Transplant. 2013 Nov;48(11):1415-20. doi: 10.1038/bmt.2013.124. Epub 2013 Aug 12. Erratum in: Bone Marrow Transplant. 2013 Nov;48(11):1488.

PMID:
23933764
8.

Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.

Walter RB, Sandmaier BM, Storer BE, Godwin CD, Buckley SA, Pagel JM, Sorror ML, Deeg HJ, Storb R, Appelbaum FR.

Biol Blood Marrow Transplant. 2015 Feb;21(2):373-8. doi: 10.1016/j.bbmt.2014.09.022. Epub 2014 Sep 30.

9.

Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.

Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ.

Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55. doi: 10.1016/j.bbmt.2014.01.009. Epub 2014 Jan 16.

10.

Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.

Antar A, Kharfan-Dabaja MA, Mahfouz R, Bazarbachi A.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.

PMID:
25550214
11.

Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.

Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG.

J Cancer Res Clin Oncol. 2016 Jan;142(1):317-24. doi: 10.1007/s00432-015-2050-y. Epub 2015 Sep 30.

PMID:
26424692
12.

Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.

Muto T, Takeuchi M, Yamazaki A, Sugita Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Aotsuka N, Iseki T, Nakaseko C.

Int J Hematol. 2015 Jul;102(1):86-92. doi: 10.1007/s12185-015-1779-z. Epub 2015 Mar 11.

PMID:
25758097
13.

Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.

Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R.

Biol Blood Marrow Transplant. 2014 Jan;20(1):46-52. doi: 10.1016/j.bbmt.2013.10.003. Epub 2013 Oct 10.

14.

Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.

Nasilowska-Adamska B, Czyz A, Markiewicz M, Rzepecki P, Piatkowska-Jakubas B, Paluszewska M, Dzierzak-Mietla M, Solarska I, Borg K, Prochorec-Sobieszek M, Szydlo R, Lewandowski K, Skotnicki A, Jedrzejczak WW, Kyrcz-Krzemien S, Komarnicki M, Warzocha K.

Eur J Haematol. 2016 Mar;96(3):236-44. doi: 10.1111/ejh.12575. Epub 2015 May 18.

PMID:
25912052
15.

Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.

Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1425-30. doi: 10.1016/j.bbmt.2015.03.022. Epub 2015 Mar 31.

16.

Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

Hefazi M, Damlaj M, Alkhateeb HB, Partain DK, Patel R, Razonable RR, Gastineau DA, Al-Kali A, Hashmi SK, Hogan WJ, Litzow MR, Patnaik MM.

Transpl Infect Dis. 2016 Dec;18(6):913-920. doi: 10.1111/tid.12612. Epub 2016 Nov 11.

PMID:
27642723
17.

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

Devillier R, Harbi S, Fürst S, Crocchiolo R, El-Cheikh J, Castagna L, Etienne A, Calmels B, Lemarie C, Prebet T, Granata A, Charbonnier A, Rey J, Chabannon C, Faucher C, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1560-5. doi: 10.1016/j.bbmt.2014.06.006. Epub 2014 Jun 14.

18.

Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.

Ishida H, Kato M, Kudo K, Taga T, Tomizawa D, Miyamura T, Goto H, Inagaki J, Koh K, Terui K, Ogawa A, Kawano Y, Inoue M, Sawada A, Kato K, Atsuta Y, Yamashita T, Adachi S.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2141-2147. doi: 10.1016/j.bbmt.2015.08.011. Epub 2015 Aug 10.

19.

Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.

Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintás-Cardama A.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):139-43. doi: 10.1016/j.clml.2012.11.004. Epub 2012 Dec 29.

20.

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A, Foá R, Milpied N, Peccatori J, Polge E, Mailhol A, Mohty M, Savani BN.

Cancer. 2017 Jul 15;123(14):2671-2679. doi: 10.1002/cncr.30646. Epub 2017 Mar 22.

Supplemental Content

Support Center